A Director at Agios Pharma (NASDAQ: AGIO) is Buying Shares

By Carrie Williams

Today, a Director at Agios Pharma (AGIOResearch Report), David Schenkein, bought shares of AGIO for $250K.

This recent transaction increases David Schenkein’s holding in the company by 1.84% to a total of $15.96 million. In addition to David Schenkein, 2 other AGIO executives reported Buy trades in the last month.

See today’s analyst top recommended stocks >>

Based on Agios Pharma’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $26.02 million and GAAP net loss of $106 million. In comparison, last year the company earned revenue of $15.2 million and had a GAAP net loss of $94.66 million. The company has a one-year high of $70.70 and a one-year low of $28.36. Currently, Agios Pharma has an average volume of 595.68K.

Starting in October 2019, AGIO received 9 Buy ratings in a row. Seven different firms, including BMO Capital and Citigroup, currently also have a Buy rating on the stock.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.